Federal and territorial funding will go toward improving access, as well as 16 infrastructure projects across 12 communities.

Health Canada approved TLANDO for testosterone replacement therapy in adult men with hypogonadism, with Lipocine’s commercial ...

CELYSTRA Pharma today announced that Health Canada has approved DAWNZERATM (donidalorsen) for the prevention of attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age ...

The only AI-powered chat created expressly for all Canadians, connecting people to trusted, practical information, and ...

Canada is recruiting internationally educated health professionals to help address health care workforce shortages, while ...

Clinical Trial Application planned for filing with Health Canada, extending the Company’s international regulatory strategy ...

Bike locks, kids toys, pregnancy tests, lawn trimmers and headphone amplifiers sold on Amazon have been recalled. See product ...

A new Fraser Institute study argued that Canada and Sweden spend nearly identical shares of GDP on universal health care, 11.6% versus 11.1% in 2025, yet Sweden consistently delivers faster access and ...

An opinion piece argues that AI should support Canada’s health workforce rather than substitute for investments in healthcare ...

For evidence that "universal" government-run health care has become an almost theological article of faith among certain segments of our society, I need look no further than some ...

The program further strengthens Canadian Hearing Services' position as a national leader in accessibility, mental health, and community support.

Following the news, Lipocine shares rose more than 25% to $2.64. TLANDO is an oral formulation of testosterone undecanoate available as 112.5 mg capsules. In January 2024, Lipocine and Verity Pharma ...